{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T00:15:16Z","timestamp":1792714516618,"version":"4.5.0"},"reference-count":36,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","license":[{"start":{"date-parts":[[2015,9,1]],"date-time":"2015-09-01T00:00:00Z","timestamp":1441065600000},"content-version":"tdm","delay-in-days":1796,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,10]]},"abstract":"<jats:sec>\n                    <jats:title\/>\n                    <jats:p>\n                      <jats:bold>Interleukin-22 (IL-22), a recently identified member of the IL-10 family of cytokines that is produced by Th17 and natural killer cells, plays an important role in controlling bacterial infection, homeostasis, and tissue repair. Here, we tested the effect of IL-22 on alcohol-induced liver injury in a murine model of chronic-binge ethanol feeding. Feeding male C57BL\/6 mice with a Lieber-DeCarli diet containing 5% ethanol for 10 days, followed by a single dose of ethanol (5 g\/kg body weight) by gavage, induces significant fatty liver and liver injury with peak serum levels of approximately 250 IU\/L alanine aminotransferase and 420 IU\/L aspartate aminotransferase 9 hours after gavage. Moreover, chronic-binge ethanol administration increases expression of hepatic and serum inflammatory cytokines and hepatic oxidative stress. Using this model, we demonstrate that treatment with IL-22 recombinant protein activates hepatic signal transducer and activator of transcription 3 (STAT3) and ameliorates alcoholic fatty liver, liver injury, and hepatic oxidative stress. Administration with IL-22 adenovirus also prevents alcohol-induced steatosis and liver injury. Deletion of STAT3 in hepatocytes abolishes the hepatoprotection provided by IL-22 in alcoholic liver injury. In addition, IL-22 treatment down-regulates the hepatic expression of fatty acid transport protein, but up-regulates several antioxidant, antiapoptotic, and antimicrobial genes. Finally, expression of IL-22 receptor 1 is up-regulated whereas IL-22 is undetectable in the livers from mice with chronic-binge ethanol feeding or patients with alcoholic hepatitis.<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion:<\/jats:title>\n                    <jats:p>\n                      <jats:bold>Chronic-binge ethanol feeding may be a useful model to study the early stages of alcoholic liver injury. IL-22 treatment could be a potential therapeutic option to ameliorate alcoholic liver disease, due to its antioxidant, antiapoptotic, antisteatotic, proliferative, and antimicrobial effects with the added benefit of potentially few side effects. Hepatology 2010<\/jats:bold>\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hep.23837","type":"journal-article","created":{"date-parts":[[2010,7,16]],"date-time":"2010-07-16T09:50:08Z","timestamp":1279273808000},"page":"1291-1300","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":391,"title":["Interleukin-22 Treatment Ameliorates Alcoholic Liver Injury in a Murine Model of Chronic-Binge Ethanol Feeding: Role of Signal Transducer and Activator of Transcription 3"],"prefix":"10.1097","volume":"52","author":[{"given":"Sung Hwan","family":"Ki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oygi","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingquan","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Oriol","family":"Morales-Ibanez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jay K.","family":"Kolls","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ramon","family":"Bataller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bin","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-16-20250312","first-page":"307328","article-title":"Alcoholic liver disease.","volume":"51","author":"OShea","year":"2010","journal-title":"Hepatology"},{"key":"R2-16-20250312","doi-asserted-by":"crossref","first-page":"27582769","DOI":"10.1056\/NEJMra0805786","article-title":"Alcoholic hepatitis.","volume":"360","author":"Lucey","year":"2009","journal-title":"N Engl J Med"},{"key":"R3-16-20250312","doi-asserted-by":"crossref","first-page":"G1G6","DOI":"10.1152\/ajpgi.00056.2004","article-title":"Recent advances in alcoholic liver disease II. Minireview: molecular mechanisms of alcoholic fatty liver.","volume":"287","author":"You","year":"2004","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R4-16-20250312","doi-asserted-by":"crossref","first-page":"19531960","DOI":"10.1053\/j.gastro.2008.08.057","article-title":"A randomized, doubleblinded, placebocontrolled multicenter trial of etanercept in the treatment of alcoholic hepatitis.","volume":"135","author":"Boetticher","year":"2008","journal-title":"Gastroenterology"},{"key":"R5-16-20250312","doi-asserted-by":"crossref","first-page":"541548","DOI":"10.1053\/j.gastro.2009.04.062","article-title":"Infection in patients with severe alcoholic hepatitis treated with steroids: early response to therapy is the key factor.","volume":"137","author":"Louvet","year":"2009","journal-title":"Gastroenterology"},{"key":"R6-16-20250312","doi-asserted-by":"crossref","first-page":"13901397","DOI":"10.1002\/hep.20206","article-title":"A doubleblind randomized controlled trial of infliximab associated with prednisolone in acute alcoholic hepatitis.","volume":"39","author":"Naveau","year":"2004","journal-title":"Hepatology"},{"key":"R7-16-20250312","doi-asserted-by":"crossref","first-page":"2434","DOI":"10.1038\/ncpgasthep0683","article-title":"Management strategies in alcoholic liver disease.","volume":"4","author":"Tilg","year":"2007","journal-title":"Nat Clin Pract Gastroenterol Hepatol"},{"key":"R8-16-20250312","doi-asserted-by":"crossref","first-page":"1731","DOI":"10.1007\/s00281-009-0188-x","article-title":"Biology of interleukin22.","volume":"32","author":"Wolk","year":"2010","journal-title":"Semin Immunopathol"},{"key":"R9-16-20250312","doi-asserted-by":"crossref","first-page":"451454","DOI":"10.1007\/s00109-009-0448-1","article-title":"IL22: a critical mediator in mucosal host defense.","volume":"87","author":"Aujla","year":"2009","journal-title":"J Mol Med"},{"key":"R10-16-20250312","doi-asserted-by":"crossref","first-page":"13321342","DOI":"10.1002\/hep.20184","article-title":"Interleukin 22 (IL22) plays a protective role in T cellmediated murine hepatitis: IL22 is a survival factor for hepatocytes via STAT3 activation.","volume":"39","author":"Radaeva","year":"2004","journal-title":"Hepatology"},{"key":"R11-16-20250312","first-page":"G74G80","article-title":"IL22 is involved in liver regeneration after hepatectomy.","volume":"298","author":"Ren X HB, Colletti","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R12-16-20250312","doi-asserted-by":"crossref","first-page":"339347","DOI":"10.1016\/j.jhep.2010.03.004","article-title":"Amelioration of high fat diet induced lipogenesis and hepatic steatosis by interleukin22.","volume":"53","author":"Yang","year":"2010","journal-title":"J Hepatol"},{"key":"R14-16-20250312","doi-asserted-by":"crossref","first-page":"224232","DOI":"10.1002\/hep.1840050212","article-title":"Severe and progressive steatosis and focal necrosis in rat liver induced by continuous intragastric infusion of ethanol and low fat diet.","volume":"5","author":"Tsukamoto","year":"1985","journal-title":"Hepatology"},{"key":"R15-16-20250312","first-page":"325330","article-title":"Animal models of alcoholic liver diseasefocus on the intragastric feeding model.","volume":"27","author":"Nanji","year":"2003","journal-title":"Alcohol Res Health"},{"key":"R16-16-20250312","doi-asserted-by":"crossref","first-page":"178187","DOI":"10.1055\/s-0029-1214373","article-title":"Second hit models of alcoholic liver disease.","volume":"29","author":"Tsukamoto","year":"2009","journal-title":"Semin Liver Dis"},{"key":"R17-16-20250312","doi-asserted-by":"crossref","first-page":"217231","DOI":"10.1080\/10915810490502069","article-title":"Earlyphase alcoholic liver disease: an update on animal models, pathology, and pathogenesis.","volume":"23","author":"Ramaiah","year":"2004","journal-title":"Int J Toxicol"},{"key":"R18-16-20250312","doi-asserted-by":"crossref","first-page":"13261334","DOI":"10.1002\/hep.22776","article-title":"An early complementdependent and TLR4independent phase in the pathogenesis of ethanolinduced liver injury in mice.","volume":"49","author":"Roychowdhury","year":"2009","journal-title":"Hepatology"},{"key":"R19-16-20250312","doi-asserted-by":"crossref","first-page":"12241231","DOI":"10.1002\/hep.22470","article-title":"The critical role of tolllike receptor (TLR) 4 in alcoholic liver disease is independent of the common TLR adapter MyD88.","volume":"48","author":"Hritz","year":"2008","journal-title":"Hepatology"},{"key":"R20-16-20250312","doi-asserted-by":"crossref","first-page":"12411250","DOI":"10.1002\/hep.23090","article-title":"Zinc supplementation reverses alcoholinduced steatosis in mice through reactivating hepatocyte nuclear factor4alpha and peroxisome proliferatoractivated receptoralpha.","volume":"50","author":"Kang","year":"2009","journal-title":"Hepatology"},{"key":"R21-16-20250312","doi-asserted-by":"crossref","first-page":"G364G374","DOI":"10.1152\/ajpgi.00456.2009","article-title":"Involvement of adiponectinSIRT1AMPK signaling in the protective action of rosiglitazone against alcoholic fatty liver in mice.","volume":"298","author":"Shen","year":"2010","journal-title":"Am J Physiol Gastrointest Liver Physiol"},{"key":"R22-16-20250312","doi-asserted-by":"crossref","first-page":"9891000","DOI":"10.1002\/hep.21138","article-title":"Differential liver sensitization to tolllike receptor pathways in mice with alcoholic fatty liver.","volume":"43","author":"Gustot","year":"2006","journal-title":"Hepatology"},{"key":"R23-16-20250312","first-page":"3348","article-title":"Intragastric ethanol infusion model in rodents.","volume":"447","author":"Tsukamoto","year":"2008","journal-title":"Methods Mol Biol"},{"key":"R24-16-20250312","doi-asserted-by":"crossref","first-page":"11481158","DOI":"10.1053\/j.gastro.2008.01.016","article-title":"Cell typedependent pro and antiinflammatory role of signal transducer and activator of transcription 3 in alcoholic liver injury.","volume":"134","author":"Horiguchi","year":"2008","journal-title":"Gastroenterology"},{"key":"R25-16-20250312","doi-asserted-by":"crossref","first-page":"687697","DOI":"10.1053\/j.gastro.2006.12.036","article-title":"Hepatic expression of candidate genes in patients with alcoholic hepatitis: correlation with disease severity.","volume":"132","author":"Colmenero","year":"2007","journal-title":"Gastroenterology"},{"key":"R26-16-20250312","doi-asserted-by":"crossref","first-page":"15451553","DOI":"10.1002\/hep.22847","article-title":"Fibrin accumulation plays a critical role in the sensitization to lipopolysaccharideinduced liver injury caused by ethanol in mice.","volume":"49","author":"Beier","year":"2009","journal-title":"Hepatology"},{"key":"R27-16-20250312","doi-asserted-by":"crossref","first-page":"214222","DOI":"10.1177\/153537020222700310","article-title":"Metallothionein protection against alcoholic liver injury through inhibition of oxidative stress.","volume":"227","author":"Zhou","year":"2002","journal-title":"Exp Biol Med (Maywood)"},{"key":"R28-16-20250312","doi-asserted-by":"crossref","first-page":"646657","DOI":"10.1002\/hep.22680","article-title":"The interleukin17 pathway is involved in human alcoholic liver disease.","volume":"49","author":"Lemmers","year":"2009","journal-title":"Hepatology"},{"key":"R29-16-20250312","doi-asserted-by":"crossref","first-page":"932941","DOI":"10.1002\/hep.23382","article-title":"Epigenetic regulation of hepatic endoplasmic reticulum stress pathways in the ethanolfed cystathionine beta synthasedeficient mouse.","volume":"51","author":"Esfandiari","year":"2010","journal-title":"Hepatology"},{"key":"R30-16-20250312","doi-asserted-by":"crossref","first-page":"572583","DOI":"10.1016\/j.jhep.2008.10.020","article-title":"The impact of CYP2E1 on the development of alcoholic liver disease as studied in a transgenic mouse model.","volume":"50","author":"Butura","year":"2009","journal-title":"J Hepatol"},{"key":"R31-16-20250312","doi-asserted-by":"crossref","first-page":"14831494","DOI":"10.1002\/hep.22222","article-title":"Cytochrome P450 2E1 contributes to ethanolinduced fatty liver in mice.","volume":"47","author":"Lu","year":"2008","journal-title":"Hepatology"},{"key":"R32-16-20250312","first-page":"92100","article-title":"Cytokines, STATs and liver disease.","volume":"2","author":"Gao","year":"2005","journal-title":"Cell Mol Immunol"},{"key":"R33-16-20250312","doi-asserted-by":"crossref","first-page":"2218622192","DOI":"10.1074\/jbc.M803510200","article-title":"Silencing of hepatic fatty acid transporter protein 5 in vivo reverses dietinduced nonalcoholic fatty liver disease and improves hyperglycemia.","volume":"283","author":"Doege","year":"2008","journal-title":"J Biol Chem"},{"key":"R34-16-20250312","doi-asserted-by":"crossref","first-page":"933941","DOI":"10.1002\/hep.20400","article-title":"Interleukin 6 alleviates hepatic steatosis and ischemiareperfusion injury in mice with fatty liver disease.","volume":"40","author":"Hong","year":"2004","journal-title":"Hepatology"},{"key":"R35-16-20250312","doi-asserted-by":"crossref","first-page":"91107","DOI":"10.1016\/0300-483X(95)03128-3","article-title":"Recombinant human interleukin6: safety issues of a pleiotropic growth factor.","volume":"105","author":"Kammuller","year":"1995","journal-title":"Toxicology"},{"key":"R36-16-20250312","doi-asserted-by":"crossref","first-page":"11071112","DOI":"10.1210\/endo-102-4-1107","article-title":"Suppression of liver cell proliferation by glucocorticoid hormone: a comparison of normally growing and regenerating tissue in the immature rat.","volume":"102","author":"Castellano","year":"1978","journal-title":"Endocrinology"},{"key":"R37-16-20250312","first-page":"G579G585","article-title":"Antibodies to tumor necrosis factoralpha inhibit liver regeneration after partial hepatectomy.","volume":"263","author":"Akerman","year":"1992","journal-title":"Am J Physiol"}],"container-title":["Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fhep.23837","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.lww.com\/01515467-201010000-00016","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T07:08:01Z","timestamp":1741763281000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/01515467-201010000-00016"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,10]]},"references-count":36,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1002\/hep.23837","relation":{},"ISSN":["0270-9139"],"issn-type":[{"value":"0270-9139","type":"print"}],"subject":[],"published":{"date-parts":[[2010,10]]}}}